Previous research has suggested that TKI treatment itself can trigger APOBEC ... of Biostatistics and Yale's Program in Computational Biology and Bioinformatics, as well as scientists from YCC ...

In cohort 1, the most common first-line treatments were tyrosine kinase inhibitors (TKI; 78.8%), followed by mammalian target of rapamycin (mTOR) inhibitors (12.4%), the investigators reported in ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC) in a multicohort phase Ia/Ib ...

Limertinib is the 14th product in Innovent's commercial portfolio and represents a cutting-edge addition to its strong TKI franchise, offering an innovative precision therapy option to lung cancer ...